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mimetic supramolecular gel†
Jonathan A. Foster,a Krishna K. Damodaran,b Antoine Maurin,c Graeme M. Day,*d
Hugh P. G. Thompson,e Gary J. Cameron,c Jenifer Cuesta Bernalc
and Jonathan W. Steed*c
We report the synthesis of a bis(urea) gelator designed to speciﬁcally mimic the chemical structure of the
highly polymorphic drug substance ROY. Crystallization of ROY from toluene gels of this gelator results in
the formation of the metastable red form instead of the thermodynamic yellow polymorph. In contrast, all
other gels and solution control experiments give the yellow form. Conformational and crystal structure
prediction methods have been used to propose the structure of the gel and show that the templation of
the red form by the targeted gel results from conformational matching of the gelator to the ROY
substrate coupled with overgrowth of ROY onto the local periodic structure of the gel ﬁbres.Introduction
The control of the solid state properties of crystalline drugs is
of tremendous importance to the pharmaceutical industry.
Active ingredient polymorphic form, particle size and crystal
morphology profoundly inuence the material's solubility,
compressibility, friability, melting point, hygroscopy, bulk
density and dissolution rate.1–3 Polymorph control also oﬀers
scope to transform an amorphous or hard-to-crystallise active
pharmaceutical ingredient (API) into a readily handled, stable
crystalline solid and is vital in obtaining regulatory approval.4
Examples of drug substances in which late-appearing or slow to
nucleate polymorphs (as in the case of ritonavir5 or clopidogrel6)
show that it can be very diﬃcult to ensure that all possible
crystal forms have been discovered. Moreover reliable identi-
cation and characterisation of polymorphic forms early in
development can avoid lengthy and costly legal disputes as in
the cefdinir case.7
In addition to careful removal of possible contaminating
‘seeds’ and highly controlled, reproducible crystallization
conditions,8 advanced crystallization techniques such as crys-
tallization from microemulsion droplets can in some casesﬃeld, Sheﬃeld, S3 7HF, UK
e, University of Iceland, Dunhagi 3, 107
ity, South Road, Durham, DH1 3LE, UK.
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Chemistry 2016reliably and selectively nucleate particular solid forms such as
the thermodynamic form under ambient conditions.9 However
there remains a signicant need for solid form screening
techniques that can target hard-to-nucleate polymorphs.
Crystallization in polymer hydrogels (e.g. agar, silica gel) of
inorganic materials such as calcium carbonate10–14 and of
biomolecules such as proteins is a well-known technique in
which the gel limits convection and prevents sedimentation,
allowing continuous, diﬀusion-limited growth15 and spatial
control of nucleation.16 The gel environment can inuence
a number of factors such as crystal habit, polymorphism and
enantiomorphism.17–21 Hydrogels22 have also been used to
crystallise pharmaceuticals such a modanil23 and the highly
polymorphic model compounds ROY and carbamazepine have
been crystallized within cubic polyethylene glycol diacrylate
microgel particles.18
We have reported a novel polymorph discovery technique
involving drug crystal growth in supramolecular organo-
gels.24–26 Supramolecular gels oﬀer a number of potential
advantages over traditional polymeric hydrogels including the
diverse range of functional groups that can be incorporated,
the wide range of solvents gelled and the ability to redissolve
the gels in order to recover the crystals. There have been a few
recent reports of crystallization within low molecular weight
supramolecular gels,21 notably work by Estroﬀ on calcite
crystallization in a bis(urea) gel,10 work by Gunnlaugsson on
salt nanowires27 and work by Sanchez involving crystallization
of aspirin, caﬀeine, indomethacin and carbamazepine in
toluene-based tetraamide organogels28 and in lysine-based
dendrons.20 In none of this work is there any suggestion of the
gelators being designed to mimic the crystallization substrate,
although carboxylates have been suggested to mimic
carbonate in calcium carbonate hydrogel crystallizations.29 AsChem. Sci.
Scheme 1 ROY and ROY-mimetic bis(urea) gelators 1 and 2.
Fig. 1 (a) Organogels formed by 2 in (left to right) dichloromethane,
chlorobenzene, 1,2-dichlorobenzene, benzene, toluene, acetonitrile,
methanol, ethanol, 1-propanol, 1-butanol, nitrobenzene and ethyl
acetate (b) SEM micrograph of the toluene xerogel of 2 at 1% w/v.
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View Article Onlinea result the gel and crystal self-assembly are essentially
orthogonal or only very weakly coupled and any diﬀerences in
polymorphism observed serendipitous.21,30
We hypothesised that incorporating molecular features into
a gelator that mimic those of the growing crystal would increase
the probability of inuencing crystal growth. In the present
work we report the design of targeted bis(urea) gelators that gel
to give a bre surface that chemically mimics a target model
drug substance, ROY,31 and oﬀers the possibility of epitaxial
crystal overgrowth and hence templation of metastable or hard-
to-nucleate solid forms in a bespoke, drug-specic manner.
ROY was rst synthesised by Eli Lilly as a precursor to
olanzapine, a schizophrenia drug.32 There are at least ten crystal
forms of ROY of which seven have been crystallographically
characterised and are kinetically stable enough to be studied
under near-ambient conditions.33 In fact, a crystal structure
prediction study of the ROY molecule has demonstrated that
even further polymorphs might be possible.34 The colours of the
ROY polymorphs originate from conformational isomerism and
allow for relatively facile in situ monitoring, with the yellow
prism form (Y) being the most stable under ambient condi-
tions.35 The substance also exhibits piezochromism.36 ROY
represents a particularly suitable model system because of its
large diversity of polymorphs, diﬃculty in controlling the crys-
tallization outcome because of seeding eﬀects and concomitant
polymorphism, and its conformational polymorphism37 which
oﬀers the possibility of conformational matching with a tar-
geted gel. Indeed one ROY polymorph has already been
discovered by epitaxial nucleation.32
Results and discussion
We have designed a series of gelators incorporating o-nitro-
aniline-derived functional groups, mimicking the o-nitroaniline
substituent in ROY, graed onto a variety of bis(urea) gel-
forming cores. We anticipate that these targeted gelators will
self-assemble to give gels38,39 in which the surface of the gel bre
consists of a locally ordered array of o-nitroaniline-derived
functional groups, closely matching the o-nitroaniline substit-
uent in ROY. The series of bis(urea) compounds were readily
prepared from the reaction of o-nitrophenylisocyanate with ve
diﬀerent diamine cores (Scheme 1 and see ESI, Scheme S1†).
The compounds were tested for gelation in a variety of solvents
and compounds 1 and 2 were found to be eﬀective gelators,
whereas the other three compounds failed to gel the majority of
the solvents tested and were not further investigated (see ESI†).
While bis(ureas) commonly give high aspect ratio solid parti-
cles, the evolution of these brillar materials into gels is subject
to solubility constraints and a subtle balance of interactions
that are not currently fully understood.40–42
Compound 1 formed gels at 1% weight to volume in almost
all solvents studied (acetonitrile, methanol, ethanol, acetone,
dichloromethane, chloroform, ethyl acetate and toluene). Gels
were not observed in water or THF. However, the gels are opa-
que and fragile, breaking apart to form a precipitate if gently
shaken. The chloroform, toluene, acetonitrile and acetone gels
are unstable and form a precipitate aer a number of daysChem. Sci.whilst gels from other solvents remain stable. The opacity of
these gels renders them unsuitable for crystallization studies
and as a result eﬀorts concentrated on compound 2.
Compound 2 forms robust, stable, translucent gels in a wide
range of solvents (see ESI†) including acetonitrile, methanol,
acetone, ethyl acetate and toluene as shown in Fig. 1.
Compound 2 is much less soluble than 1 failing to dissolve fully
in a number of the solvents at 1% w/v. Undissolved material
tends to inhibit gel formation and the use of lower concentra-
tions of gelator results in more translucent and homogeneous
gels. SEM studies on the xerogel show an entangled network of
ne bres. The translucent appearance of the gels makes them
highly suited to crystallization studies. Moreover the fact that
this gelator can gel a range of organic solvents allows a great
deal of scope to co-dissolve the gelator with drug substances of
varying solubility.24
Solutions containing 100 mg mL1 of ROY were crystallised
by slow cooling from toluene gels of the designer gelator 2, as
well as under the same conditions from toluene control solu-
tions containing either no gelator, or one of four diﬀerentThis journal is © The Royal Society of Chemistry 2016
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View Article Onlinebis(urea) gelators (3–6) with no structural similarity to ROY.
These non-specic gelators contained substituents derived
from L-alanine (3),43 L-phenylalanine (4),44 L-lysine (5) and trie-
thoxysilane (6)45 instead of the ROY-mimetic nitrophenylana-
line-derived substituent (see ESI† for gelator structures). A
further gelator with a L-phenylalanine substituent and the same
diphenylmethane derived spacer as 2 (compound 7) was also
prepared. Toluene was selected as the solvent because a wide
variety of the gelators reliably form gels in the solvent without
sonication. Samples were heated in sealed vials until all mate-
rial was dissolved and allowed to cool to room temperature on
the bench top.
Aer leaving the samples for one month all of the non-
specic generic gelators and the solution control experiment
produced large yellow blocks identied by single crystal X-ray
unit cell determination, IR spectroscopy and XRPD (see ESI
Fig. S1 and S2†) as the thermodynamically most stable mono-
clinic Y form. Under the same conditions, 1% w/v gels of 2
produced red crystals corresponding to the metastable, triclinic
red (R) form, also characterised by unit cell determination, IR
and XRPD. Fig. 2 shows images of the crystals obtained from
diﬀerent gels. These results indicate that the designer gelator, 2,
induces the crystallisation of a diﬀerent polymorph of ROY to
that obtained from solution or from a range of gels with no
structural similarity to ROY.
In order to test the generality and reproducibility of this
observation, crystallizations of ROY in toluene at concentra-
tions 50–200 mg mL1 were undertaken from gels of ROY
mimic 2. The outcome of these experiments were compared
with samples crystallized from solution and from four diﬀerent
non-specic gelators bearing either amino acid substituents (3,
4 and 7) or triethoxysilane terminal groups (6) as well as
diﬀerent spacer units between the urea functionalities. Gels
were formed with 1% w/v of gelator in each case except for
compound 3, which was used at 1.5% w/v. An additional sample
containing a non-gelling solution saturated with 2 at roomFig. 2 (a) Crystals of ROY grown from four non-speciﬁc control gels
and from gels of 2 (left to right: 3–6 and 2) and a solution phase control
experiment. (b) Isolated gel-grown crystals of the Y and R forms. (c) Y-
Form crystals growing in a toluene gel of non-speciﬁc gelator 6 (left)
and R-form crystals growing in toluene gel of 2, (right; arrows point to
individual crystals).
This journal is © The Royal Society of Chemistry 2016temperature was also investigated. The purpose of this refer-
ence was to test whether any diﬀerences observed were due to
the gel state or compound 2 acting as a solution-based crystal-
lization additive.
The crystallisations were repeated in a series of experiments
between 5 and 12 times and the results detailed in ESI Tables 1
and 2† and the collated results for samples loaded with 100 mg
mL1 ROY are summarised in Fig. 3. The optimised experi-
mental setup involved addition of 1 mL toluene to the gelator
(10 mg) and ROY (100 mg) in a vial, which was then sealed and
heated to 140 C to avoid heteroseeding. A DrySyn multi-reac-
tion station was used to in order to achieve a consistent,
controlled cooling prole. Crystallisation generally took place
over several hours to weeks. Clear diﬀerences in crystal colour
and shape allow the diﬀerent polymorphs to be distinguished.
Solid forms were conrmed by IR spectrometry and XRPD
analysis. Analyses of the crystals revealed two diﬀerent poly-
morphs identied as the Y and R forms,46 sometimes appearing
concomitantly. All the crystals formed were stable and did not
undergo any phase transition in situ aer several months.
Gels of 2 loaded with 100 mg mL1 ROY yielded the meta-
stable R form is almost every case, with only two of the twelve
repeats giving the Y form. These two anomalous results are
attributed to accidental heteroseeding with Y particles. In
contrast, the vast majority of samples from the control gelators
produced the Y form (which is the most thermodynamically
stable under ambient conditions). The control experiments in
toluene devoid of any gelator also resulted in the thermody-
namic Y form. Gelator 3 produced four Y and one R samples out
of ve whilst the remaining one gave a concomitant mixed R/YFig. 3 (a) Collated data comparing the form of ROY obtained from 100
mgmL1 toluene gels of designer gelator 2, non-speciﬁc gelators 3, 4,
6 and 7, from toluene solution saturated with 2 and from solution. R +
Y denotes concomitant crystallisation of both the R and Y crystal forms
in the same sample. (b) Crystallization of the Y form of ROY from
a toluene gel of control compound 7 and the R form from a toluene gel
of 2 (arrows point to individual crystals).
Chem. Sci.
Fig. 4 Conformational landscape of gelator 2. Each point represents
the calculated (DFT-D) energy and Connolly surface area of a pre-
dicted conformer. Selected conformers are shown, with all hydrogen
atoms hidden for clarity, apart from the urea hydrogens. Red points
show conformations with one urea group in the anti–anti confor-
mation. No conformations with both ureas in the anti–anti confor-
mation are found in this energy range. The predicted most likely
conformation, as a balance of intramolecular energy and extended-
ness, is enclosed in a blue box.
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View Article Onlinesample. Gelator 4 gave one concomitant R/Y sample, with one
sample transforming to Y aer three days and the remaining six
yielded Y crystals. Gelator 6 gave only Y crystals. Gelator 7,
which has the same spacer between the bis(urea) but a phenyl-
alanine derived end group unrelated to ROY, and therefore
potentially provides the best comparison, gave the Y form in ve
repeats whilst one gave the R form and one a mixture of the R
and Y forms.
Samples crystallised at lower concentrations of ROY (50 mg
mL1) typically took longer to crystallise and the R form was
only observed from gels of 2 with all other samples giving the Y
form. In contrast, at 200 mg mL1 of ROY, only the Y form was
observed in gels of 2 indicating high concentrations may
diminish the gel's selectivity.
The solution controls only gave the Y form (18 repeats). The Y
form was also obtained in three out of ve crystallizations from
solutions of gelator 2 at a concentration too low to result in gel
formation. This suggests that compound 2 has only a small
eﬀect on crystal growth as a solution based additive and it is the
solid bres of gels of 2 that induce formation of the R form.
On balance this screen suggests that the designer gels of 2
strongly bias ROY crystallization towards formation of the
metastable triclinic red R form. The diﬃculty in controlling
ROY polymorphic outcome from solution is well docu-
mented.31,33 In one study a solution of ROY evaporated from
10 000 500 mm gold islands on a single plate produced six out of
the seven stable forms of ROY.47 An additional factor is that in
some samples the crystals grow against the sides of the vials and
on the surface of the gels. In these cases heteronucleation on
the glass vial or from dust at the gel surface may determine the
crystal form rather than the inuence of the gel matrix. The
microscopic seeding of the Y form is also a potential con-
founding factor. In this context, the results are remarkably
clear-cut indicating that the ROY-mimetic nitrophenylaniline
substituent exerts a clear inuence on the crystallization
outcome.
In order to understand the mechanism by which gels of 2
consistently produce a diﬀerent polymorphic outcome in the
crystallization of ROY compared to other bis(urea) gels and
solution control experiments we compared the structure of 2
with the crystal structures of the R and Y forms of ROY. The
tendency of 2 to form highly anisotropic gel bres means it is
not possible to characterise 2 by single crystal X-ray diﬀraction
and powder diﬀraction gives broad, poorly dened peaks (see
ESI†). We therefore applied computational structure prediction
methods to investigate the molecular geometry of 2. The
conformational exibility of 2 means that structural determi-
nation in this way remains highly challenging.
The conformational landscape of 2 was predicted using force
eld based searches, using the OPLS-AA force eld within a low-
mode conformational search,48 followed by dispersion-cor-
rected density functional theory (DFT-D) molecular geometry
optimization. These searches found a large number of possible
conformers, the lowest energy of which adopt a compact
geometry in which nitroaniline groups on each end of the
molecule are folded together. However, a recent computational
study49 has demonstrated that exible molecules preferentiallyChem. Sci.adopt higher energy, extended conformers in the solid state,
which enables greater intermolecular interactions. We calculate
the Connolly surface area of all structures as a measure of the
extendedness of the conformer (Fig. 4). Many extended
conformers are available within the relevant energy range for
conformers in solids (approximately 25 kJ mol1),49 which open
the nitroaniline groups to a more accessible arrangement.
Although we cannot select one of the predicted conformers as
that which forms the gel, we propose that the bres are
composed of one of these extended conformers of 2. As
a predictor of which conformer is most likely, it has been sug-
gested that a biasing term based on the surface area is added to
the DFT-D conformational energies to approximate the
increased stabilizing intermolecular interactions available to
extended conformations.49 The preferred conformer with this
term included is shown in the blue box in Fig. 4.
Interestingly, few of the candidate conformers of 2 exhibited
the urea conformation that is required to form the common
urea a-tape type of packing mode based on the ubiquitous
R12(6) hydrogen bonded ring geometry.39,50,51 A relatively small
number of predicted conformers have one of the urea groups in
an anti–anti conformation (Fig. 4), where both hydrogen atoms
are oriented anti to the carbonyl oxygen. The lowest energy
conformer with both ureas in the anti–anti conformation is
found 85 kJ mol1 above the lowest energy conformer (oﬀ the
scale of Fig. 4). These results suggest that it is unlikely that the
gel bres form as a consequence of strong uni-directional
hydrogen bond tapes.
Intramolecular hydrogen bonds from the urea to nitro
groups are present in all low energy conformers of 2, forming 6-
membered rings which would be predicted by Etter's hydrogen
bonding rules.52 These intramolecular hydrogen bonds might
be expected to interfere with intermolecular hydrogen bonding.This journal is © The Royal Society of Chemistry 2016
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View Article OnlineTo explore the solid state packing of 2, crystal structure
prediction (CSP) calculations were performed on a selection of
the lowest energy and most extended predicted conformers.
Previous work has shown that CSP methods designed to predict
crystal structure can help understand the molecular arrange-
ment in gel bres.53–55 The CSP calculations involved a quasi-
random search56 for structures in a set of commonly observed
space groups, followed by lattice energy minimization with the
Crystal Optimizer57 and DMACRYS58 soware, using an atomic
multipole based atom–atom force eld. Most of the lowest
energy predicted crystal structures from both the folded and
extended molecular conformers contained R22(8) NH/O]C
hydrogen bond rings involving the non-intramolecularly
hydrogen bonded urea hydrogen. These dimeric interactions at
each end of the molecule result in innite chains (Fig. 5a),
which would be expected to lead to fast growth in the direction
of the chain.
We then attempted to correlate the CSP results with the
experimental XRPD pattern obtained from xerogels of 2. While
XRPD data for xerogels is generally broad and featureless
because of the lack of long range order in gel bres, we obtained
similar XPRD patterns from xerogels of 2 from a range of
solvents suggesting that gels of 2 adopt a similar structure
regardless of solvent. The xerogel XRPD data did not prove to be
a match for any of the calculated structures involving the folded
conformer, however the XRPD patterns corresponding to the
lowest energy calculated structures of the extended conformers
possessed considerable similarity to the experimental xerogel
XRPD data (see ESI†). Hence there is justication for regarding
packing features of the lowest energy calculated crystal struc-
tures of the extended conformer of 2, and particularly the
hydrogen bond chains of molecules, as a model for the way in
which compound 2 packs in the gel brils.
The intramolecular hydrogen bonding maintains planar
nitroaniline units at either end of the gelator molecule, which
extend outwards from the hydrogen bonded chains of mole-
cules (Fig. 5a). Therefore, the nitroaniline would be expected to
be exposed on the surface of gel bres, thus being available forFig. 5 (a) Hydrogen bond chains in the lowest energy predicted crystal
structure resulting from an extended conformer of 2. Hydrogen bonds
are indicated as thin blue lines. The conformer leading to this structure
is enclosed in a blue box in Fig. 4. (b) Overlay of the extended
conformer of 2 with the ROY conformation from the R polymorph,
showing a good steric match of the nitroaniline group to ROY. (c)
Overlay of the extended conformer of 2 with the ROY conformation
from the Y polymorph. The thiophene rings and urea are nearly at right
angles, showing a poor steric match.
This journal is © The Royal Society of Chemistry 2016interaction with ROY molecules. Signicant diﬀerences
between ROY polymorphs lie in the dihedral angle between the
phenyl and thiophene rings, and it is these conformational
diﬀerences that are responsible for the distinctive colours of the
diﬀerent solid forms. Fig. 5 shows an overlay of the molecular
structure of 2 taken from this calculated structure with the
molecular structures of ROY observed in the Y and R experi-
mental crystal structures, matching the nitrophenyl groups in
the two molecules. The thiophene orientation in the R confor-
mation gives a close steric match to the urea in 2 and aligns the
polar thiophene sulfur with the urea oxygen (Fig. 5b). In
contrast, the Y conformation places the thiophene at right
angles to the urea group in 2 (Fig. 5c). Thus, 2 gives a better
steric and electrostatic match to the R than the Y conformation
of ROY. This is a result of the intramolecular hydrogen bond,
present in all low energy conformers of 2, which strongly
favours the nearly-coplanar arrangement of urea and nitro-
phenyl groups. In the proposed structure of 2, these groups are
presented periodically on the surface of the gel bres allowing
them to interact with the growing nucleus. We thus hypothesise
that the ability of gels of 2 to template the R form from
a supersaturated solution of ROY arises from a match of the R
conformer with the periodic structure of the ROY-mimetic
portion of the gelator resulting in epitaxial overgrowth of this
metastable form. The eﬀect of conformational matching
between the gelator and ROY for R would be weakened if the
gelator conformation was exible and likely to be dynamic at
the surface of the gel bre. However, conformational dynamics
of the nitroaniline group are expected to be minimised by the
intramolecular hydrogen bond and the rigidity of the urea
group. The other control gels are likely to adopt the more
conventional urea a-tape type packing and do not possess
chemical functionality that can interact with ROY in supersat-
urated solution. As a result, the polymorphic outcome is the
same as the solution control experiments.Conclusions
In conclusion, organogels of a specically targeted gelator that
mimics the functional groups of the highly conformationally
polymorphic substrate ROY reproducibly results in the crys-
tallization of the metastable R polymorph of ROY. Under
identical conditions, crystallization from generic gels, from
solution and from solutions containing the designer gelator at
sub-critical gelation concentration all give the thermodynamic
Y form. The likely structure of the designer gelator 2 was
calculated using conformation and crystal structure predic-
tion methodologies to give insight into the structure matching
between gel and the ROY forms. The unique eﬀect of designer
gels of 2 is postulated to arise from conformational matching
with the pendant ROY-mimetic functional groups on the gel
bre surface, coupled with the local periodicity of the gel bre
allowing heteronucleation of the R form. This study demon-
strates the potential of designer supramolecular gels to be
used in a targeted way to inuence the polymorphism of
pharmaceutical compounds.Chem. Sci.
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